Background
==========

Colorectal cancer (CRC) is one of the most common cancers worldwide. It is now the third most common cancer and the fourth leading cause of cancer-related mortality in the world, accounting for approximately 1.2 million new cases per year and approximately 600 000 deaths per year worldwide \[[@b1-medscimonit-23-4422]\]. Although genetic predisposition is closely associated with some certain types of colorectal cancer, epidemiologic studies indicated that the Western lifestyle (such as in the USA) is the most important risk factor for this disease \[[@b2-medscimonit-23-4422],[@b3-medscimonit-23-4422]\]. High rates of colorectal cancer are also related to age, sex, family history, excessive alcohol consumption, diets with high animal fat, and diets low in fruit and vegetable fiber \[[@b4-medscimonit-23-4422]\].

Millions of microbiota exists in the gastrointestinal tract, and can be divided into 4 main categories: *Firmicutes*, *Bacteroides*, *Actinobacteria*, and *Proteobacteria* \[[@b5-medscimonit-23-4422],[@b6-medscimonit-23-4422]\]. The complex gut microbiota plays an indispensable role in human health, as they interact with the immune system, maintain epithelial homeostasis, metabolize indigestible polysaccharides, and exclude potential pathogens from the human gut \[[@b7-medscimonit-23-4422]\].

Colorectal cancer (CRC) screening greatly reduces CRC-related mortality and contributes to longer and healthier life \[[@b8-medscimonit-23-4422]\]. The predictive biomarkers in CRC have received much attention in recent research \[[@b9-medscimonit-23-4422]--[@b11-medscimonit-23-4422]\]. However, fecal immunochemical tests cut-off levels still need to be optimized \[[@b12-medscimonit-23-4422]\].

Recent studies have also elucidated specific traits in the gut microbiome associated with colorectal cancer and suggested that the microbiome may be useful in screening for colorectal cancer. Gut microbiota, combined with other noninvasive techniques, promises to provide highly effective tools for early colorectal cancer diagnosis and prevention \[[@b13-medscimonit-23-4422]\].

The gut microbiota has been proved to be involved in the initiation and progression of colorectal cancer. Wang et al. \[[@b14-medscimonit-23-4422]\] demonstrated that a structural difference observed in the fecal microbiota community of CRC patients was related with the non-cancerous population, and some microbiota belonging to the genera of *Enterococcus*, *Escherichia/Shigella*, *Klebsiella*, *Streptococcus*, and *Peptostreptococcus* were richer in CRC patients, while some microbiota belonging to the genus *Roseburia* and other butyrate-producing bacteria were less abundant in these patients. Some other studies found the genus *Fusobacterium* to be more predominant in colorectal adenoma and carcinoma tissues \[[@b15-medscimonit-23-4422]--[@b17-medscimonit-23-4422]\]. In addition, certain metagenomic contents and bacterial metabolites can also affect the development of CRC. For example, KEGG orthology (KO) modules for phosphotransferase systems, transporters for a number of different sugars, were overrepresented in healthy controls compared with adenoma samples or in adenoma compared with carcinoma samples, and modules for transporting the amino acids histidine, arginine, and lysine were enriched in carcinoma patients compared with adenoma patients in one study \[[@b18-medscimonit-23-4422]\]. Due to the complicated ecosystem formed by intestinal microbiota, more investigation of colorectal cancer and intestinal microbiota is needed.

In this study, we used raw high-throughput 16S ribosomal RNA (rRNA) gene sequences data on the mucosal microbiome of 160 patients. We applied some advanced statistical tools, including linear discriminant analysis effect size (LEfSe) \[[@b19-medscimonit-23-4422]\], to compare the microbiota community structure, assess differences in intestinal bacterial types between the groups, and identify metagenomic biomarkers for disparate stages of colorectal cancer formation.

Material and Methods
====================

Data collection
---------------

The data collection of 16S ribosomal RNA (rRNA) gene sequences in this research came from a published paper in "The Journal of Nature Communication" dated October 2015 and downloaded from NCBI SRA database (BioProject ID: PRJNA280026) \[[@b20-medscimonit-23-4422]\]. We recruited a total of 160 individuals: 61 cases with non-tumor colon were regarded as the normal group, 47 cases with histology-substantiated colorectal adenomas were regarded as the adenoma group, and 52 cases with invasive adenocarcinomas were regarded as the cancer group. Biopsy of the mucosa was performed for each subject. There were no significant differences in clinical parameters among the 3 groups except for age (60.13±5.99, 67.32±8.80, and 67.85±13.18 for normal, adenoma, and cancer groups, respectively) (p\<0.001).

Microbial sequence processing and analysis
------------------------------------------

USEARCH was used to process the sequences data and generate OTUs. Briefly, after quality control steps for all the sequences, UPARSE \[[@b21-medscimonit-23-4422]\] was applied to cluster sequences into OTUs with 95% similarity and select representative sequences for all the OTUs. After removing chimeras from these representative sequences using UCHIME \[[@b22-medscimonit-23-4422]\], we classified them using Ribosomal Database Project (RDP) classifiers \[[@b23-medscimonit-23-4422]\] against the Greengene database V201305 \[[@b24-medscimonit-23-4422]\]. An 80% threshold value was used to assign to a taxonomic group if a representative sequence was longer than 250 bp; otherwise, we set the threshold value to 50%. Then, we removed the OTUs if they were classified as archaea or fungi. Finally, the annotated OTUs were assigned to phylotypes according to their consensus taxonomy.

Statistical analysis
--------------------

α-diversity analysis (including the indexes of Chao1, Shannon, and Simpson) was performed using R language. Unweighted UniFrac and weighted UniFrac distance metrics analysis \[[@b25-medscimonit-23-4422]\] was carried out using QIIME \[[@b26-medscimonit-23-4422]\] and illustrated by principle coordinate analysis (PCoA). Permutational multivariate analysis of variance (PERMANOVA) \[[@b27-medscimonit-23-4422]\] was preformed to access the dissimilarities between groups using the unweighted UniFrac and weighted UniFrac distance metrics. We did it with the vegan package in R (the function of ADONIS) \[[@b28-medscimonit-23-4422]\]. The heatmap of genus information was constructed using the pheatmap package in R.

We also introduced linear discriminant analysis effect size (LEfSe) \[[@b19-medscimonit-23-4422]\], which is a very useful method to find significant metagenome markers, to identify bacterial biomarkers for all 3 groups on the open website (*<http://huttenhower.sph.harvard.edu/galaxy>*). We set an α-value \<0.05, and the threshold used to consider a discriminative feature for the logarithmic LDA score was set at \>2.

Wilcoxon and Kruskal-Wallis rank tests were conducted in R, and the p values were adjusted using Benjamin-Hochberg method. A Benjamin-Hochberg q value \<0.1 was considered to be significant.

Results
=======

Summary of the study
--------------------

A total of 1 012 335 16S rRNA sequences were obtained from the 160 samples, with an average of 6327 reads per sample in the whole cohort. The average number of reads per sample in the normal, adenoma, and cancer groups was 5547, 6968, and 6662, respectively.

We generated OTUs at 95% similarity level and the number of OTUs was 605, with 445 OTUs in the normal group, 417 OTUs in the adenoma group, and 482 OTUs in the cancer group.

Richness and diversity analysis
-------------------------------

The Chao1 Richness Index, Shannon Index, and Simpson Diversity Index were used to describe the α diversity features of our bacterial community results. We found that the Chao1 Richness Index of the mucosal microbiota was significantly different in the 3 groups (Chao1 Richness Index for normal, adenoma, and cancer group were 66.4±32.6, 61.9±29.3, and 87.8±37.5, respectively, p=0.0006, [Figure 1A](#f1-medscimonit-23-4422){ref-type="fig"}), while the Shannon Index and Simpson Index in the 3 groups were not significantly different: the Shannon Index for normal, adenoma, and cancer groups were 2.36±0.84, 2.28±0.82, and 2.59±0.70, respectively, p=0.22 ([Figure 1B](#f1-medscimonit-23-4422){ref-type="fig"}), and the Simpson Index for normal, adenoma, and cancer groups were 0.22±0.21, 0.25±0.212, and 0.17±0.13, respectively, p=0.20 ([Figure 1C](#f1-medscimonit-23-4422){ref-type="fig"}) ([Table 1](#t1-medscimonit-23-4422){ref-type="table"}).

Principal coordinate analysis (PCoA) based on the unweighted UniFrac distance metrics demonstrated that there was a separation in the mucosal bacteria communities between the 3 groups, which was confirmed by permutational multivariate analysis of variance (PERMANOVA) (ADONIS, normal-adenoma: R^2^=0.015, p=0.05; normal-cancer: R^2^=0.051, p=0.01; adenoma-cancer: R^2^=0.059, p=0.01) ([Figure 2A](#f2-medscimonit-23-4422){ref-type="fig"}). Similar results were observed in PCoA on the basis of weighted UniFrac distance metrics ([Figure 2B](#f2-medscimonit-23-4422){ref-type="fig"}).

Taxa analysis at the phylum and genus levels
--------------------------------------------

The abundance of different phyla and genera were assessed by taxonomic assignment of all sequences \[[@b14-medscimonit-23-4422]\]. Among all bacteria at the phylum level, the predominant phyla were *Bacteroidetes*, *Firmicutes*, *Fusobacteria*, and *Proteobacteria* ([Figure 3A](#f3-medscimonit-23-4422){ref-type="fig"}). Further comparison of the relative abundances of different phyla showed that there was no significant difference for any phylum between the normal and adenoma groups. However, *Firmicutes* and *Fusobacteria* were enriched in the cancer group compared with the normal and adenoma groups (*Firmicutes*: 41.87% *vs.* 33.86% in cancer and normal groups, respectively, q=0.07; 41.87% *vs.* 32.44% in cancer and adenoma groups, respectively, q=0.05. *Fusobacteria*: 17% *vs.* 9.57% in cancer and normal groups, respectively, q=0.008; 17% *vs.* 5.22% in cancer and adenoma groups, respectively, q\<0.001). Proteobacteria was relatively scarce in the cancer group compared with the normal and adenoma groups (13.34% *vs.* 31.19% *vs.* 39.92% in cancer, normal and adenoma groups, respectively, q\<0.001 for both comparisons).

There was a total of 148 genera at the genus levels, and the dominant genera were: Bacteroides (16.60%, 16.61% and 17.31% in normal, adenoma and cancer group, respectively); *Escherichia* (18.80%, 22.33% and 6.79% in 3 groups, respectively); *Fusobacterium* (9.39%, 3.12% and 14.52% in 3 groups, respectively); and *Streptococcus* (6.76%, 5.06% and 8.69% in 3 groups, respectively) ([Figure 3B](#f3-medscimonit-23-4422){ref-type="fig"}) ([Table 1](#t1-medscimonit-23-4422){ref-type="table"}).

Statistically, the relative abundances of *Campylobacter*, *Dialister*, *Fusobacterium*, *Leptotrichia*, *Mogibacterium*, *Parvimonas*, and *Peptostreptococcus* were significantly higher in cancer patients than in normal controls and adenoma patients. Higher levels of *Acidomonas*, *Escherichia*, *Pseudomonas*, and *Sphingomonas* were observed in the normal or adenoma groups compared with the cancer group. *Blautia* and *Faecalibacterium* were overrepresented in normal controls compared with the cancer group, whereas *Lactobacillus* was enriched in cancer patients compared with the normal group. *Prevotella*, a genus belonging to the phylum *Bacteroidetes*, was more abundant in the cancer group than in the adenoma group. Consistent with the outcomes of phylum levels, no significant difference in the genus levels was found between the normal and adenoma groups.

Identification of key taxa (biomarkers) responsible for structural diversion of the mucosa-associated microbiota
----------------------------------------------------------------------------------------------------------------

We used the linear discriminative analysis (LDA) effect size (LEfSe) biomarker discovery tool to assess which microbiota were driving divergence between different groups, using the parameters described above. Biomarker discovery was performed at all taxonomic levels. At the genus level, *Acidomonas* (LDA=3.8, p\<0.01), *Butyricicoccus* (LDA=2.9, p=0.04), *Micrococcus* (LDA=3.1, p=0.04), and *Sphingomonas* (LDA=3.6, p\<0.01) were the biomarkers for the normal group. *Bacillus* (LDA=3.5, p=0.05), *Eikenella* (LDA=2.5, p\<0.01), *Enhydrobacter* (LDA=2.8, p\<0.01), *Escherichia* (LDA=4.9, p\<0.01), *Klebsiella* (LDA=3.7, p=0.04), *Paenibacillus* (LDA=3.3, p=0.01), *Pseudomonas* (LDA=3.9, p\<0.01), *Staphylococcus* (LDA=4.1, p\<0.01), and *Trabulsiella* (LDA=4.1, p=0.03) were the biomarkers for the adenoma group. In the cancer group, we observed 20 biomarkers. Eleven genera belonged to the phylum *Firmicutes*: *Bulleidia* (LDA=3.7, p=0.01); *Catonella* (LDA=2.8, p=0.02); *Clostridium* (LDA=3.5, p=0.05); *Dialister* (LDA=3.1, p\<0.01); *Granulicatella* (LDA=4.0, p=0.04); *Lactobacillus* (LDA=3.3, p\<0.01); *Mogibacterium* (LDA=3.2, p=0.01); *Oscillospira* (LDA=3.4, p=0.01); *Parvimonas* (LDA=4.4, p\<0.01); *Peptostreptococcus* (LDA=4.0, p\<0.01); and *Streptococcus* (LDA=4.3, p=0.03). Four genera belonged the phylum *Bacteroidetes*: *Odoribacter* (LDA=2.9, p=0.01); *Paraprevotella* (LDA=4.0, p\<0.01); *Porphyromonas* (LDA=3.6, p=0.02); and *Prevotella* (LDA=4.1, p\<0.01). Two belonged to *Fusobacteria*: *Fusobacterium* (LDA=4.7, p\<0.01) and *Leptotrichia* (LDA=4.1, p\<0.01). Two belonged to *Proteobacteria*: *Campylobacter* (LDA=4.1, p\<0.01) and *Desulfovibrio* (LDA=3.1, p=0.02). One belonged to *Spirochaetes*: *Treponema* (LDA=3.4, p\<0.01). Most of these microbiota had an LDA score higher than 3.0 ([Figure 4](#f4-medscimonit-23-4422){ref-type="fig"}).

Discussion
==========

Although the etiology of CRC is multifactorial and complex, there is increasing evidence that gut microbiota and their metabolism are closely linked to CRC development \[[@b29-medscimonit-23-4422]\]. In our study, we revealed differing mucosa-associated microbiota structure with the development of CRC, which has been addressed by several other publications \[[@b20-medscimonit-23-4422],[@b30-medscimonit-23-4422],[@b31-medscimonit-23-4422]\]. Similar microbial shift has also been reported in IBDs such as Crohn's disease (CD) \[[@b17-medscimonit-23-4422]\] and ulcerative colitis (UC) \[[@b32-medscimonit-23-4422]\], as well as in diarrhea \[[@b33-medscimonit-23-4422]\] and IBS \[[@b34-medscimonit-23-4422]\].

*Fusobacterium*, a genus belonging to the phylum *Fusobacteria*, has been reported to be able to potentiate CRC. Kostic et al. \[[@b35-medscimonit-23-4422]\] reported that a specific strain of *Fusobacterium*, *F. nucleatum*, increased tumor burden and selectively expanded myeloid-derived immune cells like CD11b^+^ myeloid cells and myeloid-derived suppressor cells (MDSCs) in Apc^Min/+^ mice. They also observed a strong correlation between F. nucleatum abundance and expression of proinflammatory markers such as COX-2, IL-8, IL-6, IL-1b, and TNF-α in the mouse experiments and human colon samples. Kostic et al. suggested that *Fusobacteria* create a proinflammatory microenvironment that is favorable for colorectal carcinogenesis through recruitment of tumor-infiltrating immune cells. Rubinstein et al. \[[@b36-medscimonit-23-4422]\] showed the adhesin FadA, a virulence factor found in *F. nucleatum* \[[@b37-medscimonit-23-4422]\], mediates the growth of CRC cells via activation of β-catenin signaling by binding to E-cadherin. Furthermore, the antitumor activity of immune cell can be inhibited by Fap2 protein of *F. nucleatum* via TIGIT (T cell immunoreceptor with Ig and ITIM domains), which in turn promotes CRC development \[[@b38-medscimonit-23-4422]\]. In the present study, we observed a greater abundance of *Fusobacterium* in cancer tissues than in normal tissues (14.52% *vs.* 9.39%, respectively, q=0.02) and adenoma tissues (14.52% *vs.* 3.12%, respectively, q=0.00). Thus, the increased abundance of *Fusobacterium* could be linked with high risk of CRC. Some CRC-associated biomarkers, such as *Parvimonas*, *Peptostreptococcus*, and the species *Porphyromonas endodontalis* (LDA=3.3, p=0.002), were also identified in our study. These microbes can corporate with other bacteria of oral origin such as *Fusobacterium* to form a strong symbiotic network. Further studies on their potential oncogenic functions will reveal whether there are drivers or passengers in colorectal tumorigenesis \[[@b20-medscimonit-23-4422]\].

Another CRC-related pathogen identified in our study is *Bacteroides fragilis* (LDA=4.6, p\<0.01). Enterotoxigenic *B. fragilis*, a commensal in the human colon, triggers colitis and induces colonic tumors via a selective T helper type 17 (T~H~17) response \[[@b39-medscimonit-23-4422]\]. Non-toxigenic *B. fragilis* can suppressing inflammatory response in animal experimental colitis models induced by *Helicobacter hepaticus* infection through a single microbial molecule (polysaccharide A, PSA) \[[@b40-medscimonit-23-4422]\]. Thus, more detailed studies at the gene or strain level are required for a comprehensive understanding of gut microbes in the pathogenesis of CRC. Moreover, *Prevotella*, of the phylum *Bacteroidetes*, was enriched in the cancer group (3.57% of the total) compared with the normal (1.45% of the total) and adenoma groups (0.47% of the total). Although *Prevotella* is more common in non-Westerners, who prefer a plant-rich diet \[[@b41-medscimonit-23-4422]\], and an increased level of *Prevotella* accompanied by some special dietary intervention creates a propitious condition for glucose metabolism \[[@b42-medscimonit-23-4422]\], it is also relevant in some inflammatory conditions like arthritis \[[@b43-medscimonit-23-4422]\]. Protein-rich diets tend to be rich in arginine and tryptophan. Arginine and tryptophan are linked by an entwined pathway in immunometabolism and their joint modulation could be an important target for effective immunotherapy in several diseases \[[@b44-medscimonit-23-4422]\]. Further research is needed on the potential role of *Prevotella* in CRC.

One feature of the compositional imbalance in the gut microbiota of CRC patients is a depletion of some SCFA (short chain fatty acids)-producing microbes. SCFAs, including acetate, propionate, and butyrate, are absorbed rapidly by colonic epithelial cells \[[@b45-medscimonit-23-4422]\]. Acetate enters the blood and is used primarily for lipogenesis by peripheral tissues, and propionate is mainly used by hepatocytes for the function of gluconeogenesis, while butyrate is a major energy source for colon cells \[[@b46-medscimonit-23-4422]--[@b48-medscimonit-23-4422]\]. These small molecules can help maintain normal function of colonic epithelial cells, exert an anti-inflammatory role, and inhibit tumor cell growth \[[@b49-medscimonit-23-4422],[@b50-medscimonit-23-4422]\]. Notably, Faecalibacterium prausnitzii has shown a potential effect as a probiotic in the treatment of Crohn's disease \[[@b51-medscimonit-23-4422]\]. In our study, we detected a higher level of *F. Prausnitzii* (8.88% *vs.* 4.54%, respectively, q=0.03) and *Blautia* (5.96% *vs.* 2.78%, respectively, q=0.02) in the normal group than in the cancer group. Our data suggest a protective role of SCFA-producing bacteria in CRC.

*Escherichia coli* is one of the most abundant commensals in the human gut. It is reported that *E. coli* is associated with IBD \[[@b52-medscimonit-23-4422]\]. In addition, certain *E. coli* strains that harbor the polyketide synthetase (pks) island are able to induce DNA damage, which in turn increases the mutation rate of infected cells and leads to tumor progression \[[@b53-medscimonit-23-4422]\]. In our study, we detected a lower level of *E. coli* in cancer patients (6.76%) than in health controls (18.80%) and adenoma patients (22.33%). *E. coli* was a candidate adenoma-associated biomarker. These phenomena can partly be explained by the bacterial driver-passenger model for CRC, in which some drivers like *E. coli* colonize on the colonic mucosa of individuals susceptible to developing CRC, which changes the microenvironment in favor of adenoma-carcinoma processes, and then are outcompeted by passengers who are likely to flourish in the altered microenvironment \[[@b54-medscimonit-23-4422]\].

Our study has certain limitations. We were unable to unravel the causal relationship between gut microbiota and CRC. Because we only collected data after diagnosis of colorectal tumor, the differences in bacterial composition could be a consequence of CRC. For example, there is always a lower pH in the tumor environment \[[@b55-medscimonit-23-4422]\], and Walker et al. discovered that a tiny change in pH will cause massive fluctuations in gut microbes, including the genus *Fusobacterium* \[[@b56-medscimonit-23-4422]\]. The genetic phenotype proved to be associated with the disease was not investigated in our study. Therefore, a better way to illustrate the roles of gut microbiota in CRC is through gut microbiota transplantation from healthy donors \[[@b57-medscimonit-23-4422]\]. Due to interpersonal variations in gut microbiota, some mixed factors could not be balanced. The cancer patients in our study tended to be older than in the other 2 groups, and age has a fundamental influence on gut microbiota (e.g., older people tend to have a higher proportion of *Bacteroides* spp. and distinct abundance patterns of *Clostridium* groups) \[[@b58-medscimonit-23-4422]\]. Diet, lifestyle, and genetics can also affect gut microbiome structure. Further studies controlling these factors are needed for a more comprehensive demonstration of the possible influence of intestinal microflora on CRC.

Conclusions
===========

In conclusion, our study showed differences in gut microbial composition by comparing normal individuals with patients in 2 stages of CRC-adenoma and adenocarcinoma. We also identified some bacteria such as *Butyricicoccus*, *E. coli*, and *Fusobacterium* that can be used as potential biomarkers for normal, adenoma, and cancer groups, respectively.
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![Taxa analysis at the phylum and genus levels. (**A**) Proportions of main bacterial phyla in the 3 groups. (**B**) Relative abundances of some major genera across all samples. Each row represents 1 genus and each column represents 1 sample. The first row shows the groups of every sample (red). The clustering tree of samples was generated using euclidean distance with complete method. The color intensity of each genus is proportional to its relative abundance in each sample.](medscimonit-23-4422-g003){#f3-medscimonit-23-4422}
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###### 

Richness and diversity analysis and bacteria at the phylum level in this study.

                         Normal group n=61   Adenoma group n=47   Cancer group n=52
  ---------------------- ------------------- -------------------- -------------------
  Chao1 Richness Index   66.4±32.6           61.9±29.3            87.8±37.5
  Shannon Index          2.36±0.84           2.28±0.82            2.59±0.70
  Simpson Index          0.22±0.21           0.25±0.212           0.17±0.13
  *Firmicutes*           33.86%              32.44%               41.87%
  *Fusobacteria*         9.57%               5.22%                17%
  *Proteobacteria*       31.19%              39.92%               13.34%
  *Bacteroides*          16.60%              16.61%               17.31%
  *Escherichia*          18.80%              22.33%               6.79%
  *Fusobacterium*        9.39%               3.12%                14.52%
  *Streptococcus*        6.76%               5.06%                8.69%
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